CASI Pharmaceuticals Operating Expenses Growth & History (CASIF)
CASI Pharmaceuticals's operating expenses was $55.1M for fiscal 2025.
View full CASI Pharmaceuticals company overviewCASI Pharmaceuticals annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $55.1M | $4.3M | +8.50% |
| 2024 | 2024-12-31 | $50.8M | $5.6M | +12.49% |
| 2023 | 2023-12-31 | $45.1M | −$16.2M | −26.39% |
| 2022 | 2022-12-31 | $61.3M | $2.2M | +3.70% |
| 2021 | 2021-12-31 | $59.1M | $713,000 | +1.22% |
| 2020 | 2020-12-31 | $58.4M | — | — |
CASI Pharmaceuticals quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $15.3M | −$235,000 | −1.51% |
| Q3 2025 | 2025-09-30 | $10.9M | — | — |
| Q2 2025 | 2025-06-30 | $12.8M | — | — |
| Q1 2025 | 2025-03-31 | $13.9M | — | — |
| Q4 2024 | 2024-12-31 | $15.6M | — | — |
CASI Pharmaceuticals operating expenses trends
Over the last five fiscal years, CASI Pharmaceuticals's operating expenses decreased from $58.4M to $55.1M, a change of −$3.3M. The latest reported quarter, Q4 2025, shows $15.3M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CASI Pharmaceuticals source filings ↗